These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12709295)

  • 1. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
    Clark W; Raftery J; Song F; Barton P; Cummins C; Fry-Smith A; Burls A
    Health Technol Assess; 2003; 7(3):1-67. PubMed ID: 12709295
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(15):2179-208. PubMed ID: 16225377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C; Selinger CP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
    Tang DH; Armstrong EP; Lee JK
    Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
    Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
    Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab use in Crohn's disease: impact on health care resources in the UK.
    Jewell DP; Satsangi J; Lobo A; Probert C; Forbes A; Ghosh S; Shaffer J; Frenz M; Drummond H; Troy G; Turner S; Younge L; Evans L; Moosa M; Rodgers-Gray B; Buchan S
    Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1047-52. PubMed ID: 16148549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use.
    Koelewijn C; Schrijvers A; Oldenburg B
    Neth J Med; 2006; 64(7):212-8. PubMed ID: 16929082
    [No Abstract]   [Full Text] [Related]  

  • 8. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
    Jobanputra P; Barton P; Bryan S; Burls A
    Health Technol Assess; 2002; 6(21):1-110. PubMed ID: 12387732
    [No Abstract]   [Full Text] [Related]  

  • 9. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J; Punekar YS; Morris J; Chung-Faye G
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorrect cost of infliximab in fistulizing Crohn's disease.
    Lichtenstein GR
    Gastroenterology; 2004 Aug; 127(2):691-2; author reply 692-3. PubMed ID: 15300614
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.
    Bodger K; Kikuchi T; Hughes D
    Aliment Pharmacol Ther; 2009 Aug; 30(3):265-74. PubMed ID: 19438428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
    Wong JB; Singh G; Kavanaugh A
    Am J Med; 2002 Oct; 113(5):400-8. PubMed ID: 12401535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic implications of biological therapies for Crohn's disease: review of infliximab.
    Bodger K
    Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
    Kobelt G; Jönsson L; Young A; Eberhardt K
    Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease.
    Bell SJ; Kamm MA
    Aliment Pharmacol Ther; 2000 May; 14(5):501-14. PubMed ID: 10792111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Funding the new biologics--a health economic critique of the CCOHTA report: infliximab for the treatment of Crohn's disease.
    Mitton CR;
    Can J Gastroenterol; 2002 Dec; 16(12):873-6. PubMed ID: 12522479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
    Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
    J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.